The effect of bosentan on plasma ischemia-modified albumin levels in acute mesenteric ischemia
MetadataShow full item record
CitationGulpinar, K., Ozdemir, S., Ozis, E., Aydin, S., & Korkmaz, A. (2013). The effect of bosentan on plasma ischemia-modified albumin levels in acute mesenteric ischemia. Nobel Medicus, 9(2), 96-99. https://www.webofscience.com/wos/woscc/full-record/WOS:000323802900019
Objective: Our aim in this study was to examine the effects of bosentan, an orally active antagonist of endothelin A and B receptors, on plasma ischemia-modified albumin (IMA) levels in mesenteric ischemia induced rats. Material and Method: In this randomized, controlled trial 36 mature female wistor rats were divided into three groups. Group 1 (n=12) was the control group which only laparotomy was performed. Group 2 (n=12) was the ischemia group and group 3 (n=12) was the bosentan pretreated (100 mg/kg-1 day, 1 gavage/day for two days before surgery) ischemia group. In the ischemia groups (GR 2 and GR 3) following laparotomy the superior mesenteric artery was clamped using a bulldog clamp during laparotomy. Blood samples were taken at 30 minutes from all groups and IMA levels were studied. Results: Plasma IMA levels in the ischemia group (GR 2) was significantly higher compared to those of the control (p<0.001) and bosentan pretreated group (GR 3) (p=0.002). Serum IMA levels were higher in GR 3 than control group but there were no statistical significance (p=0.659). Conclusion: These preliminary results suggest that bosentan might have a protective effect in mesenteric ischemic conditions.